BRPI0212266B8 - anticorpos humanizados anti-ccr4, método de produção dos mesmos, medicamento, e agentes terapêuticos e de diagnóstico - Google Patents
anticorpos humanizados anti-ccr4, método de produção dos mesmos, medicamento, e agentes terapêuticos e de diagnósticoInfo
- Publication number
- BRPI0212266B8 BRPI0212266B8 BRPI0212266A BRPI0212266B8 BR PI0212266 B8 BRPI0212266 B8 BR PI0212266B8 BR PI0212266 A BRPI0212266 A BR PI0212266A BR PI0212266 B8 BRPI0212266 B8 BR PI0212266B8
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- ccr4
- therapeutic
- drug
- production
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- 229940039227 diagnostic agent Drugs 0.000 title abstract 2
- 239000000032 diagnostic agent Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 4
- 101150081315 CCR4 gene Proteins 0.000 abstract 3
- 108091008927 CC chemokine receptors Proteins 0.000 abstract 1
- 102000005674 CCR Receptors Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000001772 blood platelet Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4719—G-proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001265144 | 2001-08-31 | ||
PCT/JP2002/008828 WO2003018635A1 (en) | 2001-08-31 | 2002-08-30 | Human cdr-grafted antibodies and antibody fragments thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
BR0212266A BR0212266A (pt) | 2004-10-19 |
BRPI0212266B1 BRPI0212266B1 (pt) | 2020-05-05 |
BRPI0212266B8 true BRPI0212266B8 (pt) | 2021-05-25 |
Family
ID=19091652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0212266-9 BRPI0212266B8 (pt) | 2001-08-31 | 2002-08-30 | anticorpos humanizados anti-ccr4, método de produção dos mesmos, medicamento, e agentes terapêuticos e de diagnóstico |
Country Status (23)
Country | Link |
---|---|
US (8) | US7504104B2 (pt) |
EP (1) | EP1449850B9 (pt) |
JP (1) | JP4052515B2 (pt) |
KR (1) | KR100959248B1 (pt) |
CN (1) | CN100430420C (pt) |
AT (1) | ATE490277T1 (pt) |
AU (1) | AU2002338015B8 (pt) |
BE (1) | BE2019C006I2 (pt) |
BR (1) | BRPI0212266B8 (pt) |
CA (1) | CA2458627C (pt) |
CO (1) | CO5560582A2 (pt) |
CY (2) | CY1111193T1 (pt) |
DE (1) | DE60238503D1 (pt) |
DK (1) | DK1449850T3 (pt) |
ES (1) | ES2356190T3 (pt) |
FR (1) | FR19C1028I2 (pt) |
HK (1) | HK1073851A1 (pt) |
LU (1) | LUC00116I2 (pt) |
MX (1) | MXPA04001894A (pt) |
NL (1) | NL300985I2 (pt) |
NO (1) | NO334858B1 (pt) |
PT (1) | PT1449850E (pt) |
WO (1) | WO2003018635A1 (pt) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2270147T4 (da) * | 1999-04-09 | 2020-08-31 | Kyowa Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle |
CN100455599C (zh) | 2000-03-03 | 2009-01-28 | 协和发酵工业株式会社 | 基因重组抗体及其抗体片段 |
US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
EP1491209A4 (en) * | 2002-02-28 | 2006-05-17 | Kyowa Hakko Kogyo Kk | MEANS FOR DIAGNOSIS AND TREATMENT OF INTERSTITIAL PNEUMONIA |
AU2003236017B2 (en) | 2002-04-09 | 2009-03-26 | Kyowa Kirin Co., Ltd. | Drug containing antibody composition |
AU2004277466C1 (en) | 2003-10-01 | 2022-06-23 | Kyowa Kirin Co., Ltd. | Method of stabilizing antibody and stabilized solution-type antibody preparation |
CA2542037A1 (en) * | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Composition of antibody capable of specifically binding ccr4 |
WO2005053741A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | ケモカイン受容体ccr4に対する遺伝子組換え抗体を含む医薬 |
PT2805728T (pt) | 2003-12-23 | 2020-04-08 | Genentech Inc | Novos anticorpos anti-il13 e o uso dos mesmos |
US20060034841A1 (en) * | 2004-06-07 | 2006-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of depleting regulatory T cell |
CA2597717C (en) | 2005-02-18 | 2014-10-21 | Dana-Farber Cancer Institute | Antibodies against cxcr4 and methods of use thereof |
WO2007013627A1 (ja) * | 2005-07-28 | 2007-02-01 | Kyowa Hakko Kogyo Co., Ltd. | Bリンパ腫およびホジキンリンパ腫の治療剤 |
US20080118978A1 (en) | 2006-04-28 | 2008-05-22 | Takashi Sato | Anti-tumor agent |
GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
US8962806B2 (en) * | 2007-12-28 | 2015-02-24 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
JP5552630B2 (ja) * | 2008-10-24 | 2014-07-16 | 学校法人 聖マリアンナ医科大学 | Htlv−i関連脊髄症を治療または予防するための医薬、およびhtlv−i関連脊髄症の患者に対する抗体療法の効果を試験する方法 |
GB0909906D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
ES2502541T3 (es) * | 2009-09-10 | 2014-10-03 | Kyowa Hakko Kirin Co., Ltd. | Medicamento que incluye una composición de anticuerpos unida específicamente al receptor 4 de quimiocina CC humana (CCR4) |
CN102863533B (zh) * | 2010-06-21 | 2013-12-11 | 中国科学技术大学 | 抗体人源化改造方法 |
AU2011289426A1 (en) | 2010-08-10 | 2013-02-28 | Amgen Inc. | Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies |
GB201020738D0 (en) | 2010-12-07 | 2011-01-19 | Affitech Res As | Antibodies |
US10266599B2 (en) | 2010-12-07 | 2019-04-23 | Cancer Research Technology Limited | Antibodies which bind to the human CC chemokine receptor 4 and uses thereof |
NZ609493A (en) | 2010-12-16 | 2015-11-27 | Genentech Inc | Diagnosis and treatments relating to th2 inhibition |
US11492383B2 (en) | 2011-06-24 | 2022-11-08 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
EP2870973B1 (en) * | 2012-07-06 | 2022-08-31 | St. Marianna University School of Medicine | Remedy for htlv-1-associated myelopathy patients |
CA3174012A1 (en) | 2013-09-13 | 2015-03-19 | Genentech, Inc. | Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products |
KR102571391B1 (ko) | 2013-09-13 | 2023-08-29 | 제넨테크, 인크. | 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물 |
JP2017517506A (ja) | 2014-05-21 | 2017-06-29 | ファイザー・インコーポレイテッド | 癌を処置するための抗ccr4抗体および4−1bbアゴニストの併用 |
TW201713332A (zh) | 2015-07-14 | 2017-04-16 | 協和醱酵麒麟有限公司 | 包含與抗體組合投予之ido抑制物之腫瘤治療劑 |
EP3471753A1 (en) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
CN111465618A (zh) * | 2017-12-12 | 2020-07-28 | 宏观基因有限公司 | 双特异性cd16-结合分子及其在疾病治疗中的用途 |
CN108250290B (zh) * | 2018-02-23 | 2024-03-12 | 上海捌加壹医药科技有限公司 | Ccr4的n端重组蛋白及其用途 |
CN116731186B (zh) * | 2023-07-07 | 2023-12-26 | 武汉爱博泰克生物科技有限公司 | 抗人IgG-Fc兔单克隆抗体及其制备方法、多核苷酸分子、表达载体和宿主细胞 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5608039A (en) * | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
US5914110A (en) | 1993-09-07 | 1999-06-22 | Smithkline Beecham Corporation | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
JPH0853355A (ja) | 1994-08-12 | 1996-02-27 | Taisho Pharmaceut Co Ltd | Il−5産生抑制剤 |
GB9501683D0 (en) | 1995-01-27 | 1995-03-15 | Glaxo Group Ltd | Substances and their uses |
US6498015B1 (en) | 1995-06-07 | 2002-12-24 | Icos Corporation | Methods of identifying agents that modulate the binding between MDC and an MDC receptor |
AU690474B2 (en) | 1995-09-11 | 1998-04-23 | Kyowa Hakko Kirin Co., Ltd. | Antibody againts alpha-chain of human interleukin 5 receptor |
IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
DE69835441T2 (de) | 1997-11-12 | 2007-08-02 | F. Hoffmann-La Roche Ag | Behandlung von t-helfer zell typ 2 vermittelten immunkrankheiten mit retinoid antagonisten |
US6355244B1 (en) | 1997-11-17 | 2002-03-12 | University Of Kentucky Research Foundation | Methods and compositions for the treatment of psoriasis |
AU753131B2 (en) | 1998-06-26 | 2002-10-10 | Chugai Seiyaku Kabushiki Kaisha | Remedies for hypercalcemic crisis |
US6245332B1 (en) | 1999-01-15 | 2001-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of systemic memory T cell trafficking |
US6488930B1 (en) | 1999-01-15 | 2002-12-03 | Millennium Pharmaceuticals, Inc. | Anti-CCR4 antibodies and methods of use therefor |
EP1050307A1 (en) | 1999-05-06 | 2000-11-08 | Applied Research Systems ARS Holding N.V. | CCR4 antagonists in sepsis |
CN100455599C (zh) * | 2000-03-03 | 2009-01-28 | 协和发酵工业株式会社 | 基因重组抗体及其抗体片段 |
WO2005053741A1 (ja) * | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | ケモカイン受容体ccr4に対する遺伝子組換え抗体を含む医薬 |
-
2002
- 2002-08-30 DE DE60238503T patent/DE60238503D1/de not_active Expired - Lifetime
- 2002-08-30 CN CNB02820882XA patent/CN100430420C/zh not_active Expired - Lifetime
- 2002-08-30 PT PT02770179T patent/PT1449850E/pt unknown
- 2002-08-30 ES ES02770179T patent/ES2356190T3/es not_active Expired - Lifetime
- 2002-08-30 EP EP02770179A patent/EP1449850B9/en not_active Expired - Lifetime
- 2002-08-30 JP JP2003523494A patent/JP4052515B2/ja not_active Expired - Lifetime
- 2002-08-30 CA CA2458627A patent/CA2458627C/en not_active Expired - Lifetime
- 2002-08-30 US US10/231,452 patent/US7504104B2/en active Active
- 2002-08-30 MX MXPA04001894A patent/MXPA04001894A/es active IP Right Grant
- 2002-08-30 AT AT02770179T patent/ATE490277T1/de active
- 2002-08-30 BR BR0212266-9 patent/BRPI0212266B8/pt not_active IP Right Cessation
- 2002-08-30 KR KR1020047002852A patent/KR100959248B1/ko active IP Right Grant
- 2002-08-30 AU AU2002338015A patent/AU2002338015B8/en active Active
- 2002-08-30 WO PCT/JP2002/008828 patent/WO2003018635A1/ja active Application Filing
- 2002-08-30 DK DK02770179.6T patent/DK1449850T3/da active
-
2004
- 2004-02-27 CO CO04017609A patent/CO5560582A2/es active IP Right Grant
- 2004-03-01 NO NO20040976A patent/NO334858B1/no not_active IP Right Cessation
-
2005
- 2005-08-01 HK HK05106562.0A patent/HK1073851A1/xx not_active IP Right Cessation
-
2009
- 2009-02-27 US US12/395,214 patent/US7842797B2/en not_active Expired - Lifetime
-
2010
- 2010-10-13 US US12/903,780 patent/US8143058B2/en not_active Expired - Fee Related
-
2011
- 2011-02-14 CY CY20111100175T patent/CY1111193T1/el unknown
-
2012
- 2012-03-23 US US13/428,739 patent/US20120177643A1/en not_active Abandoned
-
2013
- 2013-04-22 US US13/867,693 patent/US8900584B2/en not_active Expired - Lifetime
-
2014
- 2014-03-17 US US14/215,556 patent/US9051371B2/en not_active Expired - Fee Related
-
2015
- 2015-05-04 US US14/703,469 patent/US10131711B2/en not_active Expired - Lifetime
-
2017
- 2017-08-11 US US15/675,154 patent/US10590203B2/en not_active Expired - Fee Related
-
2019
- 2019-04-19 FR FR19C1028C patent/FR19C1028I2/fr active Active
- 2019-04-25 CY CY2019022C patent/CY2019022I1/el unknown
- 2019-04-25 BE BE2019C006C patent/BE2019C006I2/fr unknown
- 2019-04-26 LU LU00116C patent/LUC00116I2/en unknown
- 2019-05-06 NL NL300985C patent/NL300985I2/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0212266B8 (pt) | anticorpos humanizados anti-ccr4, método de produção dos mesmos, medicamento, e agentes terapêuticos e de diagnóstico | |
Peck et al. | A phase 1, randomized, single-ascending-dose study to investigate the safety, tolerability, and pharmacokinetics of DSTA4637S, an anti-Staphylococcus aureus thiomab antibody-antibiotic conjugate, in healthy volunteers | |
Lonial et al. | Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma | |
Hanna et al. | A phase II study of methylphenidate for the treatment of fatigue | |
BRPI0509127A (pt) | agentes terapêuticos para distúrbios do ouvido interno contendo um antagonista de il-6 como ingredientes ativo | |
WO2004050016A3 (en) | Delivery of pharmaceutical agents via the human insulin receptor | |
Caimi et al. | The antiCD19 antibody drug immunoconjugate loncastuximab achieves responses in DLBCL relapsing after antiCD19 CAR-T cell therapy | |
Tøttrup et al. | Continuous versus short-term infusion of cefuroxime: assessment of concept based on plasma, subcutaneous tissue, and bone pharmacokinetics in an animal model | |
ES2138729T3 (es) | Metodos de diagnostico de la preeclampsia. | |
ES2080037T1 (es) | Medicamento de uso topico con actividad cicatrizante. | |
WO2002017893A3 (de) | Sgk2 und sgk3 als diagnostische und therapeutische targets | |
BR112022003811A2 (pt) | Tratamento de retinopatia diabética com fab anti vegf totalmente humano modificado pós tradução | |
Price et al. | Intracranial phycomycosis: a clinicopathological and radiological study | |
Chandra et al. | Test‐dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non‐malignant disorders | |
Rowinsky et al. | Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. | |
Patel et al. | Characteristics and clinical assessment of antibiotic delivery by chitosan sponge in the high-risk diabetic foot: a case series | |
Hoffstedt et al. | Penetration of ceftazidime into extracellular fluid in patients | |
Daly et al. | Pharmacokinetic study of islatravir and etonogestrel implants in macaques | |
WO1998032429A3 (en) | P2 receptor agonists, antagonists and modulators of endogenous atp release for the treatment of skin conditions and the improvement of wound healing | |
Kumar et al. | Nicotine self-administration with menthol and audiovisual cue facilitates differential packaging of CYP2A6 and cytokines/chemokines in rat plasma extracellular vesicles | |
Trinquand et al. | Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study | |
Strauss et al. | Conventional psychotropic-induced tremor extinguished by olanzapine | |
Wheatley | Additional conditions amenable to observation care | |
Sahu et al. | Ultrasound-guided platelet-rich plasma infiltration: A stupendous treatment for chronic tendinopathy | |
Seah et al. | Effect of Therapeutic Plasma Exchange on Itraconazole Pharmacokinetics: A Case Study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: KYOWA HAKKO KIRIN CO., LTD. (JP) |
|
B25G | Requested change of headquarter approved |
Owner name: KYOWA HAKKO KIRIN CO., LTD. (JP) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: KYOWA KIRIN CO., LTD. (JP) |
|
B25G | Requested change of headquarter approved |
Owner name: KYOWA KIRIN CO., LTD. (JP) |
|
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/05/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/08/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 30/08/2022 |